Cisplatin-induced Nephrotoxicty and its Predisposing Factors for Unrecovered Kidney Injury: A Report from Indonesia National Cancer Center
DOI:
https://doi.org/10.3889/oamjms.2023.11128Keywords:
Cisplatin, Nephrotoxicity, Chemotherapy, Kidney injury, ToxicityAbstract
BACKGROUND: Cisplatin-induced nephrotoxicity is the most common and devastating side effects which affects long-term outcome. It may be reversible in some patients but may also cause permanent kidney injury.
AIM: This research aims to evaluate risk factors of cisplatin nephrotoxicity and unrecovered kidney function at national cancer hospital in Indonesia.
METHODS: This is a retrospective and cohort study conducted at Dharmais National Cancer Hospital, Jakarta, Indonesia. All cancer patients aged 18 years old and above, who received cisplatin-based regimen as the first-line chemotherapy and completing all cycles with at least four cycles, were included in the study. Demographic data were collected and kidney function was evaluated using estimated glomerular filtration rate (eGFR) before, 3 times during chemotherapy, 1 and 3 months after the last dose.
RESULTS: A total of 177 patients were included in the analysis, with mean age of 45.80 ± 11.75 years old, majority diagnosed with nasopharynx cancer (58.8%), and have baseline eGFR of 102.76 ± 20.68 mL/min 1.73m2. Nephrotoxicity is occurred in 80 (45.2%) patients with 27 (15.3%) toxicity occurred after the first cycle. Age above 50, hypertension and non-steroidal anti-inflammatory drugs (NSAID) use associated with increased risk of cisplatin-induced nephrotoxicity. Nephrotoxicity risk factors include age above 50 (OR 4.18, 95% CI 2.11–8.28; p < 0.0001), hypertension (OR 2.03, 95% CI 1.03–4.01; p = 0.040), and NSAID use (OR 2.34, 95% CI 1.22–4.93; p = 0.025). Risk factors of patients who unrecovered above 75% eGFR baseline were hypertension (OR 0.47, 95% CI 0.17–0.56; p = 0.001) and gender (OR 0.018, 95% CI 0.03–0.95; p = 0.043).
CONCLUSION: Nephrotoxicity occurs in 45.2% patients throughout cisplatin-based chemotherapy cycles. Risk factors of nephrotoxicity includes age above 50, hypertension, and NSAID while hypertension and female gender are risk factor for not recover above 75% eGFR baseline after cisplatin cycles.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Pabla N, Dong Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994-1007. https://doi.org/10.1038/sj.ki.5002786 PMid:18272962
Santos ML, de Brito BB, da Silva FA, Botelho AC, de Melo. Nephrotoxicity in cancer treatment: An overview. World J Clin Oncol. 2020;11(4):190-204. https://doi.org/10.5306/wjco.v11.i4.190 PMid:32355641
Al-Naimi MS, Rasheed HA, Hussien NR, Al-Kuraishy HM, Al-Gareeb AI. Nephrotoxicity: Role and significance of renal biomarkers in the early detection of acute renal injury. J Adv Pharm Technol Res. 2019;10(3):95-9. https://doi.org/10.4103/japtr.JAPTR_336_18
Crona DJ, Faso A, Nishijima TF, Mcgraw KA, Galsky MD, Milowsky MI. A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist. 2017;22(5):609-19. https://doi.org/10.1634/theoncologist.2016-0319 PMid:28438887
Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, et al. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS One. 2014;9(7):e101902. https://doi.org/10.1371/journal.pone.0101902 PMid:25020203
Almanric K, Marceau N, Cantin A, Bertin É. Risk factors for nephrotoxicity associated with cisplatin. Can J Hosp Pharm. 2017;70(2):99-106. https://doi.org/10.4212/cjhp.v70i2.1641 PMid:28487576
Ruggiero A, Rizzo D, Trombatore G, Maurizi P, Riccardi R. The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: Real or not? Cancer Chemoter Pharmacol. 2016;77(1):19-26. https://doi.org/10.1007/s00280-015-2913-6 PMid:26589789
Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23(5):460-4. https://doi.org/10.1016/s0270-9295(03)00089-5 PMid:13680535
Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int. 2014;2014:967826. https://doi.org/10.1155/2014/967826 PMid:25165721
Ishitsuka R, Miyazaki J, Ichioka D, Inoue T, Kageyama S, Sugimoto M, et al. Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients. Clin Exp Nephrol. 2017;21(4):732-40. https://doi.org/10.1007/s10157-016-1327-z PMid:27565169
Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: A systematic review and meta- analysis. Kidney Int. 2012;81(5):442-8. https://doi.org/10.1038/ki.2011.379 PMid:22113526
Odutayo A, Wong CX, Farkouh M, Altman DG, Hopewell S, Emdin CA, et al. AKI and long-term risk for cardiovascular events and mortality. J Am Soc Nephrol. 2017;28(1):377-87. https://doi.org/10.1681/ASN.2016010105 PMid:27297949
Villeneuve PM, Clark EG, Sikora L, Sood MM, Bagshaw SM. Health-related quality-of-life among survivors of acute kidney injury in the intensive care unit: A systematic review. Intensive Care Med. 2016;42(2):137-46. https://doi.org/10.1007/s00134-015-4151-0 PMid:26626062
Silver SA, Chertow GM. The economic consequences of acute kidney injury. Nephron. 2017;137(4):297-301. https://doi.org/10.1159/000475607 PMid:28595193
Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: The renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110(6):1376-84. https://doi.org/10.1002/cncr.22904 PMid:17634949
Isiiko J, Atwiine B, Oloro J. Prevalence and risk factors of nephrotoxicity among adult cancer patients at Mbarara regional referral hospital. Cancer Manag Res. 2021;13:7677-84. https://doi.org/10.2147/CMAR.S326052 PMid:34675664
Miyoshi T, Misumi N, Hiraike M, Mihara Y, Nishino T, Tsuruta M, et al. Risk factors associated with cisplatin-induced nephrotoxicity in patients with advanced lung cancer. Biol Pharm Bull. 2016;39(12):2009-14. https://doi.org/10.1248/bpb.b16-00473 PMid:27904042
Galfetti E, Cerutti A, Ghielmini M, Zucca E, Wannesson L. Risk factors for renal toxicity after inpatient cisplatin administration. BMC Pharmacol Toxicol. 2020;21(1):19. https://doi.org/10.1186/s40360-020-0398-3 PMid:32122396
Máthé C, BohácsA, Duffek L, Lukácsovits J, Komlosi ZI, Szondy K, et al. Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients. Eur Respir J. 2011;37(4):888-94. https://doi.org/10.1183/09031936.00055110
PMid:20650984
Yoshida T, Niho S, Toda M, Goto K, Yoh K, Umemura S, et al. Protective effect of magnesium preloading on cisplatin- induced nephrotoxicity: A retrospective study. Jpn J Clin Oncol. 2014;44(4):346-54. https://doi.org/10.1093/jjco/hyu004 PMid:24503028
De Jongh FE, van Veen RN, Veltman SJ, de Wit R, van der Burg ME, van den Bent MJ, et al. Weekly high-dose cisplatin is a feasible treatment option: Analysis on prognostic factors for toxicity in 400 patients. Br J Cancer. 2003;88(8):1199-206. https://doi.org/10.1038/sj.bjc.6600884 PMid:12698184
Moon HH, Seo KW, Yoon KY, Shin YM, Choi KH, Lee SH. Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients. World J Gastroenterol. 2011:17(30):3510-7. https://doi.org/10.3748/wjg.v17.i30.3510 PMid:21941418
Sato K, Watanabe S, Ohtsubo A, Shoji S, Ishikawa D, Tanaka T, et al. Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors. BMC Cancer. 2016;16:222. https://doi.org/10.1186/s12885-016-2271-8 PMid:26979596
Wen J, Zeng M, Shu Y, Guo D, Sun Y, Guo Z, et al. Aging increases the susceptibility of cisplatin-induced nephrotoxicity. Age (Dordr). 2015;37(6):112. https://doi.org/10.1007/s11357-015-9844-3 PMid:26534724
Liu JQ, Cai GY, Wang SY, Song YH, Xia YY, Liang S, et al.
Therapeutics and clinical risk management dovepress the characteristics and risk factors for cisplatin-induced acute kidney injury in the elderly. Ther Clin Risk Manag. 2018;14:1279-85. https://doi.org/10.2147/TCRM.S165531 PMid:30100726
Lavolé A, Danel S, Baudrin L, Gounant V, Ruppert AM, Epaud C, et al. Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic. Bull Cancer. 2012;99(4):E43-8. https://doi.org/10.1684/bdc.2012.1555 PMid:22450449
Michels J, Spano JP, Brocheriou I, Deray G, Khayat D, Izzedine H. Acute tubular necrosis and interstitial nephritis during pemetrexed therapy. Case Rep Oncol. 2009;2(1):53-6. https://doi.org/10.1159/000208377 PMid:20740145
Londrino F, Zattera T, Trezzi M, Palumbo R, Granata A, Tatangelo P, et al. Pemetrexed-induced acute kidney failure following irreversible renal damage: Two case reports and literature review. J Nephropathol. 2016;6(2):43-8. https://doi.org/10.15171/jnp.2017.07 PMid:28491851
De Rouw N, Boosman RJ, van de Bruinhorst H, Biesma B, van den Heuvel MM, Burger DM, et al. Cumulative pemetrexed dose increases the risk of nephrotoxicity. Lung Cancer. 2020;146:30-5. https://doi.org/10.1016/j.lungcan.2020.05.022 PMid:32505078
Gelen V, Şengül E, Yıldırım S, Senturk E, Tekin S, Kükürt A. The protective effects of hesperidin and curcumin on 5-fluorouracil-induced nephrotoxicity in mice. Environ Sci Pollut Res Int. 2021;28(34):47046-55. https://doi.org/10.1007/s11356-021-13969-5 PMid:33886055
Shord SS, Thompson DM, Krempl GA, Hanigan MH. Effect of concurrentmedicationsoncisplatin-inducednephrotoxicityinpatients with head and neck cancer. Anticancer Drugs. 2006;17(2):207-15. https://doi.org/10.1097/00001813-200602000-00013 PMid:16428940
Mohri J, Katada C, Ueda M, Sugawara M, Yamashita K, Moriya H, et al. Predisposing factors for chemotherapy-induced nephrotoxicity in patients with advanced esophageal cancer who received combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil. J Transl Int Med. 2018;6(1):32-7. https://doi.org/10.2478/jtim-2018-0007 PMid:29607302
Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: A review. Am J Med Sci. 2007;334(2):115-24. https://doi.org/10.1097/maj.0b013e31812dfe1e PMid:17700201
Ma Z, Hu X, Ding HF, Zhang M, Huo Y, Dong Z. Single-nucleus transcriptional profiling of chronic kidney disease after cisplatin nephrotoxicity. Am J Pathol. 2022;192(4):613-28. https://doi.org/10.1016/j.ajpath.2021.12.012 PMid:35092726
Fu Y, Cai J, Li F, Liu Z, Shu S, Wang Y, et al. Chronic effects of repeated low-dose cisplatin treatment in mouse kidneys and renal tubular cells. Am J Physiol Renal Physiol. 2019;317(6):F1582-92. https://doi.org/10.1152/ajprenal.00385.2019 PMid:31532246
Downloads
Published
How to Cite
License
Copyright (c) 2023 Noorwati Sutandyo, Puteri Wahyuni, Sri Agustini Kurniawati, Hilman Tadjoedin, Devina Adella (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)
